Natural Product (NP) Details
General Information of the NP (ID: NP3882) | |||||
---|---|---|---|---|---|
Name |
L-canavanine
|
||||
Synonyms |
canavanine; L-canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-((Aminoiminomethyl)amino)homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; GGB; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; C5H12N4O3; HSDB 3471; L(+)-Canavanine; Spectrum_001137; Tocris-0673; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Prestwick3_000609; Spectrum2_000800; Spectrum3_001206; Spectrum4_000783; Spectrum5_001884; Lopac-C-9758; bmse000073; Lopac0_000320; BSPBio_000518; BSPBio_002592; KBioGR_001226; KBioSS_001617; DivK1c_000360; O-carbamimidamido-L-homoserine; SCHEMBL151097; SPECTRUM1500833; SPBio_000940; BPBio1_000570; DTXSID5045041; HMS501B22; KBio1_000360; KBio2_001617; KBio2_004185; KBio2_006753; KBio3_002092; NINDS_000360; HMS1921K08; ZINC3869452; BDBM50271982; BDBM50370459; CCG-40178; AKOS006240676; DB01833; SDCCGMLS-0066683.P001; SDCCGSBI-0050308.P003; IDI1_000360; SMP1_000062; NCGC00015287-01; NCGC00015287-18; NCGC00015287-19; NCGC00024722-01; NCGC00024722-02; NCGC00024722-03; NCGC00024722-04; (2S)-2-amino-4-guanidinooxy-butanoic acid; (S)-2-Amino-4-(guanidinooxy)butanoic acid; O-{[Amino(imino)methyl]amino}-L-homoserine; X6876; Butyric acid, 2-amino-4-(guanidinooxy)-, L; C00308; (2S)-2-amino-4-(carbamimidamidooxy)butanoic acid; L-Alpha-amino-gamma-[guanidinooxy]-N-butyric acid; Q418408; L-Homoserine, O-((aminoiminomethyl)amino)- (9CI); [Eur.J.Pharmacol. 269:269; 271:87 (1994)]; UNII-QXB6XSA047 component FSBIGDSBMBYOPN-VKHMYHEASA-N; (2s)-2-amino-4-(((diaminomethylidene)amino)oxy)butanoic acid; 56C22C33-8657-4884-BE16-CAF24BF61D77; L-Canavanine, >=98% (TLC), powder, from Canavalia ensiformis
Click to Show/Hide
|
||||
Species Origin | Canavalia ensiformis ... | Click to Show/Hide | |||
Canavalia ensiformis | |||||
Disease | Acute lymphoblastic leukemia [ICD-11: 2B33] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C5H12N4O3
|
||||
PubChem CID | |||||
Canonical SMILES |
C(CON=C(N)N)C(C(=O)O)N
|
||||
InChI |
1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1
|
||||
InChIKey |
FSBIGDSBMBYOPN-VKHMYHEASA-N
|
||||
CAS Number |
CAS 543-38-4
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
In-vivo Model | Male Fishcher rats weighing 150-175 g were used in this study. | |||||
Experimental
Result(s) |
Combination therapy offers a viable means of improving L-canavanine's intrinsic efficacy while decreasing the concentration of 5-FU required to produce the same cytotoxic effect. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Nitric-oxide synthase endothelial (NOS3) | Molecule Info | [3] | |
BioCyc | Citrulline-nitric oxide cycle | Click to Show/Hide | ||
KEGG Pathway | Arginine and proline metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | Calcium signaling pathway | |||
4 | cGMP-PKG signaling pathway | |||
5 | HIF-1 signaling pathway | |||
6 | Sphingolipid signaling pathway | |||
7 | PI3K-Akt signaling pathway | |||
8 | VEGF signaling pathway | |||
9 | Platelet activation | |||
10 | Estrogen signaling pathway | |||
11 | Oxytocin signaling pathway | |||
NetPath Pathway | Wnt Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | Endothelin signaling pathway | |||
3 | Interleukin signaling pathway | |||
4 | PI3 kinase pathway | |||
5 | VEGF signaling pathway | |||
Pathway Interaction Database | Plasma membrane estrogen receptor signaling | Click to Show/Hide | ||
2 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
3 | Angiopoietin receptor Tie2-mediated signaling | |||
4 | Thromboxane A2 receptor signaling | |||
5 | SHP2 signaling | |||
6 | VEGFR1 specific signals | |||
7 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
8 | PAR1-mediated thrombin signaling events | |||
Reactome | ROS production in response to bacteria | Click to Show/Hide | ||
2 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
3 | eNOS activation | |||
4 | Nitric oxide stimulates guanylate cyclase | |||
5 | VEGFR2 mediated vascular permeability | |||
WikiPathways | ACE Inhibitor Pathway | Click to Show/Hide | ||
2 | EGF/EGFR Signaling Pathway | |||
3 | Myometrial Relaxation and Contraction Pathways | |||
4 | JAK/STAT | |||
5 | Corticotropin-releasing hormone | |||
6 | AGE/RAGE pathway | |||
7 | Endothelin Pathways | |||
8 | Leptin signaling pathway | |||
9 | Effects of Nitric Oxide | |||
10 | Metabolism of nitric oxide | |||
11 | Angiogenesis |
